A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms THEMIS
- Sponsors AstraZeneca
- 22 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Nov 2018.
- 22 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2018.
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting.